Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Fangya Tan"'
Autor:
Jie Yang, Jian-Guo Zhou, Benjamin Frey, Hu Ma, Haitao Wang, Markus Hecht, Rainer Fietkau, Udo Gaipl, Xiaofei Chen, Ada Hang-Heng Wong, Fangya Tan, Si-Si He, Gang Shen, Yun-Jia Wang, Wenzhao Zhong
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective Fast progression (FP) represents a desperate situation for advanced non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor therapy. We aimed to develop a predictive framework based on machine learning (ML) method
Externí odkaz:
https://doaj.org/article/20e430b979254079aac5e5c334ae163c
Publikováno v:
Bioengineering, Vol 11, Iss 8, p 818 (2024)
This study uses machine learning to identify critical factors influencing the cost-effectiveness of over-the-counter (OTC) medications. By developing a novel cost-effectiveness rating (CER) based on user ratings and prices, we analyzed data from Amaz
Externí odkaz:
https://doaj.org/article/ce06a4b4f0d14e0c96538c073609cde9
Publikováno v:
Forecasting, Vol 5, Iss 1, Pp 127-137 (2023)
Since May 2022, over 64,000 Monkeypox cases have been confirmed globally up until September 2022. The United States leads the world in cases, with over 25,000 cases nationally. This recent escalation of the Monkeypox outbreak has become a severe and
Externí odkaz:
https://doaj.org/article/51bd90e435c24c95913d780570e87a5d
Autor:
Jian-Guo Zhou, Ada Hang-Heng Wong, Haitao Wang, Su-Han Jin, Fangya Tan, Yu-Zhong Chen, Si-Si He, Gang Shen, Benjamin Frey, Rainer Fietkau, Markus Hecht, Shamus R. Carr, Ruihong Wang, Bo Shen, David S. Schrump, Hu Ma, Udo S. Gaipl
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
ImportanceBlood cell count test (BCT) is a robust method that provides direct quantification of various types of immune cells to reveal the immune landscape to predict atezolizumab treatment outcomes for clinicians to decide the next phase of treatme
Externí odkaz:
https://doaj.org/article/0510a79ed4e94420ac663f83d39095e3
Autor:
Jian-Guo Zhou, Ada Hang-Heng Wong, Haitao Wang, Fangya Tan, Xiaofei Chen, Su-Han Jin, Si-Si He, Gang Shen, Yun-Jia Wang, Benjamin Frey, Rainer Fietkau, Markus Hecht, Hu Ma, Udo S. Gaipl
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundDevelopment of severe immune-related adverse events (irAEs) is a major predicament to stop treatment with immune checkpoint inhibitors, even though tumor progression is suppressed. However, no effective early phase biomarker has been establ
Externí odkaz:
https://doaj.org/article/5e92e0567a3346cc9a5c65ab03834cfe
Autor:
Jian-Guo, Zhou, Ada Hang-Heng, Wong, Haitao, Wang, Fangya, Tan, Xiaofei, Chen, Su-Han, Jin, Si-Si, He, Gang, Shen, Yun-Jia, Wang, Benjamin, Frey, Rainer, Fietkau, Markus, Hecht, Hu, Ma, Udo S, Gaipl
BackgroundDevelopment of severe immune-related adverse events (irAEs) is a major predicament to stop treatment with immune checkpoint inhibitors, even though tumor progression is suppressed. However, no effective early phase biomarker has been establ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdcbb1b31c28a421224a332eb2174eb4
https://opus4.kobv.de/opus4-fau/files/19843/DataSheet_2.pdf
https://opus4.kobv.de/opus4-fau/files/19843/DataSheet_2.pdf
Autor:
Jian-Guo Zhou, Jie Yang, Haitao Wang, Ada Hang-Heng Wong, Fangya Tan, Xiaofei Chen, sisi he, Gang Shen, Yun-Jia Wang, Benjamin Frey, Rainer Fietkau, Markus Hecht, Wen-Zhao Zhong, Hu Ma, Udo Gaipl
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::757fc5ef584be61ead3c7144837b7579
https://doi.org/10.2139/ssrn.4214527
https://doi.org/10.2139/ssrn.4214527
Autor:
Jian-Guo Zhou, Udo S. Gaipl, Rui-Hong Wang, Su-Han Jin, Fangya Tan, Shamus R. Carr, David S. Schrump, Hu Ma, Bo Shen, Markus Hecht, Si-si He, Rainer Fietkau, Ada Hang-Heng Wong, Benjamin Frey, Yu-Zhong Chen, Haitao Wang, Gang Shen
IntroductionImmune checkpoint inhibitor (ICI) therapy is a major breakthrough in non-small cell lung cancer (NSCLC) treatment. However, valid predictive biomarkers are lacking. Blood cell count test (BCT) provides a direct quantification of various t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da9d0add585f182f72b0e6511b79eb76
https://doi.org/10.1101/2021.08.28.21262770
https://doi.org/10.1101/2021.08.28.21262770
Autor:
Jian-Guo Zhou, Xiaofei Chen, Ada Hang-Heng Wong, Haitao Wang, Fangya Tan, Si-Si He, Gang Shen, YunJia Wang, Ruihong Wang, Shamus R. Carr, Benjamin Frey, Rainer Fietkau, Markus Hecht, Hu Ma, David S. Schrump, Udo S Gaipl
Publikováno v:
Journal of Clinical Oncology. 40:e21113-e21113
e21113 Background: Numerous studies suggested that pre-treatment C-reactive protein (CRP) is a survival predictive biomarker for cancer patients treated with anti-PD-(L)1 blockade. However, the application of longitudinal CRP levels as dynamic biomar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ab5e0a4bb8448c3ca6726af59941310
https://doi.org/10.1200/jco.2022.40.16_suppl.e21113
https://doi.org/10.1200/jco.2022.40.16_suppl.e21113
Autor:
Si-si He, Jian-Guo Zhou, Udo S. Gaipl, Markus Hecht, Bo Shen, Fangya Tan, Su-Han Jin, Hu Ma, Rainer Fietkau, Ada Hang-Heng Wong, Yu-Zhong Chen, Benjamin Frey, Haitao Wang, Gang Shen
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A355-A355
BackgroundImmune checkpoint inhibitor (ICI) therapy is a major breakthrough for non-small cell lung cancer (NSCLC) treatment given its high efficacy and tolerable toxicity. Although pre-treatment PD-L1 expression levels and tumor mutation burden (TMB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73f2b34b35f1597b5fc89d6f399f096b
https://doi.org/10.1136/jitc-2021-sitc2021.329
https://doi.org/10.1136/jitc-2021-sitc2021.329